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Introduction
The human multidrug resistance P-glycoprotein (P-gp) uses ATP to transport structurally diverse compounds out of the cell (recently reviewed in (1, 2) ). The protein contributes to the phenomenon of multidrug resistance because many of the drugs used in AIDS and cancer chemotherapy are substrates of P-gp (3, 4) . P-gp is a member of the ATP-Binding Cassette (ABC) family of transporters. The 1280 amino acids of P-gp are arranged as two repeating units of 610 amino acids that are joined by a linker region of about 60 amino acids (5) . Each repeat has six transmembrane (TM) segments and a hydrophilic domain containing an ATP-binding site (6) (7) (8) . The minimum functional unit is a monomer (9) , but the two halves of the molecule do not have to be covalently linked for function (10, 11) . Both ATP-binding sites are required for activity (7, (12) (13) (14) and likely function in an alternating mechanism (15). Studies on deletion mutants have shown that the TM domains alone are sufficient to mediate drug binding (11) . Studies on the activity of cysteine mutants and their inhibition by different thiol-reactive substrate analogs indicate that residues from multiple TM segments contribute to the drug-binding site (16) (17) (18) (19) (20) (21) .
To determine the mechanism of P-gp, it is important to understand how drug binding and subsequent efflux are coupled to ATP hydrolysis. A key step in the reaction cycle is activation of ATP hydrolysis when the drug-binding site is occupied. It is not known whether drug-stimulated ATPase activity requires that the drug-binding site alternate between occupied and unoccupied states or if ATPase activity is permanently activated when the drug-binding site is permanently occupied. 
Experimental Procedures
Construction of Mutants -A histidine-tagged Cys-less P-gp cDNA was constructed (6, 22) . The presence of the histidine tag facilitated purification of the mutant P-gps by nickel-chelate chromatography (23). Single cysteine residues were then introduced into the predicted TM segments of Cys-less P-gp(His)10 as described previously (18) .
Expression, Reaction with MTS-verapamil, Purification and Measurement of Drugstimulated ATPase Activities of P-gp Mutants -
The histidine-tagged P-gp mutants were expressed in HEK 293 cells. After 24 h, the media was replaced with fresh media containing 10 mM cyclosporin A. Cyclosporin A acts as a specific chemical chaperone to promote maturation of P-gp and increases the yield of P-gp (24, 25) . After another 24 h, the transfected cells from fifty 10-cm diameter culture plates were washed 3 times with PBS (phosphate buffered saline, pH 7.4) and suspended in 1.5 ml of PBS. The cells were solubilized by addition of one volume of PBS containing 2 % (w/v) n-dodecyl-b-Dmaltoside. Insoluble material was removed by centrifugation at 16,000 x g for 15 min at 4 o C. Half of the supernatant (1.3 ml) was mixed with 8 ml DMSO (control) and the other half mixed with 8 ml of 50 mM MTS-verapamil (in DMSO; final concentration 0.3 mM). The mixtures were incubated for 10 min at 22 o C, cooled to 4 o C and then 150 ml of 3 M NaCl and 50 ml of 1 M imidazole (pH 7.0) were added. P-gp(His)10 was then isolated by nickelchelate chromatography as described previously (23) . The recovery of P-gp was monitored by immunoblot analysis with rabbit anti P-gp polyclonal antibody (9). To protect P-gp from labeling with MTS-verapamil, 0.5 mM cyclosporin A, 5 mM demecolcine, 5 mM verapamil, Inhibition of ATPase activity by vanadate was done by addition of an equal volume of buffer containing 100 mM Tris-HCl, pH 7.4, 100 mM NaCl, 20 mM MgCl2, 10 mM ATP and 0.2 mM orthovanadate to the P-gp-lipid mixture (26) . Orthovanadate was prepared from Na3VO4, pH 10 and boiled for 2 min to break down polymeric species before use (28).
Results
Drug transport by P-gp involves the coupling of drug binding with ATP hydrolysis.
The transport cycle predicts the existence of an activated intermediate. Therefore, the goal in this study was to determine whether P-gp could be trapped as an activated intermediate if drug substrates could be prevented from leaving the drug-binding site. An approach to keep the drug-binding site occupied would be to permanently attach a drug substrate to a residue in the drug-binding site. Cysteine-scanning mutagenesis and reaction with a thiolreactive analog of a drug substrate seemed ideal for these studies. We have done cysteine-scanning mutagenesis on all the residues in the TM segments and found that almost all of the single cysteine mutants were active (16) (17) (18) .
A useful thiol-reactive drug substrate is MTS-verapamil ( Fig. 1) . It is an analog of verapamil and contains an alkylthiosulfonate group that reacts selectively with cysteine residues (29, 30) . We previously showed that MTS-verapamil is a good substrate of Cysless P-gp as it stimulated its ATPase activity 10-fold and with a Km of 25 mM (Km for verapamil, 25 mM) (19) . Accordingly, a cysteine was introduced at each position in the predicted TM segments of Cys-less P-gp(His)10. A total of 252 mutants were made, expressed in HEK 293 cells and then solubilized with 1%(w/v) n-dodecyl-b-D-maltoside.
Insoluble material was removed by centrifugation and the samples treated with or without 0.3 mM MTS-verapamil. This concentration of MTS-verapamil caused maximum activation of Cys-less P-gp (19). P-gp was then immobilized on a nickel-chelate column, washed with buffer to remove unbound MTS-verapamil and eluted from the column. The ATPase activities of the P-gp treated with and without MTS-verapamil were determined. One mutant, I306C, showed an 8-fold increase in ATPase activity after treatment with MTSverapamil. Activation by MTS-verapamil was concentration dependent. Fig. 1 shows that maximal stimulation occurred after treatment of mutant I306C with 0.1 to 1 mM MTSverapamil and half-maximal stimulation was 39 mM. Nickel-chelate chromatography was effective in removing unreacted MTS-verapamil because the activity of Cys-less P-gp remained at basal levels even after pretreatment with 1 mM MTS-verapamil (Fig. 1) .
To test if all of mutant I306C had been modified by MTS-verapamil, we assayed for stimulation or inhibition of the ATPase activity by other drug substrates. The rationale is that if a significant amount unmodified mutant I306C is present, then the presence of other substrates or inhibitors should affect the activity of the mutant. We tested compounds that are potent stimulators (calcein-AM, demecolcine, vinblastine, verapamil) (17, (31) (32) (33) or inhibitors (cyclosporin A, trans-(E)-flupentixol) of P-gp ATPase activity (33) (34) (35) . Fig. 2 shows the effect of various stimulators and inhibitors on the ATPase activity of mutant I306C before and after treatment with MTS-verapamil. Before treatment with MTSverapamil, the ATPase activity of mutant I306C was stimulated by demecolcine, calcein-AM, verapamil and vinblastine by 11.9-, 9.8-, 7-and 3-fold, respectively. By contrast, cyclosporin A and trans-(E)-flupentixol inhibited the ATPase activity (0.9-and 0.5-fold, respectively). When mutant I306C was pretreated with MTS-verapamil, the presence of other stimulators or inhibitors of P-gp had little effect on its ATPase activity (7.7-to 8.1-fold versus 8-fold increase) (Fig. 2) . This inability to further stimulate or inhibit the activity of the MTS-verapamil-treated mutant I306C suggest that most (more than 90%) of the mutant I306C P-gp was modified and that covalent attachment of verapamil in the drug-binding site blocks access of other drug substrates to the drug-binding site.
It was possible that reaction of the mutant with MTS-verapamil partially denatured the protein so that the ATP binding sites are uncoupled from the drug-binding sites. If modified I306C retained a 'native' structure, then it should be possible to restore basal levels of ATPase activity if covalent attachment of MTS-verapamil was removed. Accordingly, modified I306C was treated with 20 mM dithiothreitol to reduce the disulfide bond between P-gp and MTS-verapamil, and then P-gp was re-isolated by nickel-chelate chromatography. Fig. 3 shows that reduction of the disulfide bond by dithiothreitol reduced the activity of the mutant as its ATPase activity was only slightly higher (1.5-fold) than the untreated I306C mutant. Mutant I306C remained active after removal of the covalentlybound MTS-verapamil since it retained the ability to be stimulated by verapamil (6.9-fold).
The characteristics of the ATPase activity of modified I306C mutant were also examined. We tested for vanadate trapping of nucleotide. P-gp traps nucleotides in the presence of vanadate plus Mg-ATP and results in the formation of an inhibitory transition state that inhibits ATP hydrolysis at the second ATP site (36) . Fig. 3 shows that mutant I306C that had been labeled with MTS-verapamil was still inhibited by vanadate. In addition, the modified mutant I306C had a Km for ATP (1.1 mM) that was very similar to that of Cys-less P-gp (1 mM) (data not shown). These results suggest that the compounds tested likely share a common drug-binding site.
Discussion
Treatment of mutant I306C with MTS-verapamil followed by removal of unreacted MTS-verapamil caused the mutant to remain in an activated state. ATP is constantly hydrolyzed at a high rate without concomitant transport, i.e. ATP hydrolysis is uncoupled from vectorial transport. Addition of other stimulators or inhibitors of P-gp could not change the ATPase activity of the activated mutant. An explanation for this observation is that covalent attachment of MTS-verapamil to the cysteine residue at position 306 in TM5 resulted in the permanent occupation of the drug-binding site in an orientation similar to that of P-gp with unmodified verapamil. Evidence that MTS-verapamil tethered to I306C mimics the interaction of the mutant with verapamil is that both verapamil and MTSverapamil caused similar activation of ATPase activity (7-to 8-fold). In addition, activation of I306C by MTS-verapamil was reversed by dithiothreitol and the dithiothreitol-treated mutant could rebind verapamil. Both MTS-verapamil and verapamil must bind to the same drug-binding site because the activity of MTS-verapamil-treated I306C was not affected by verapamil or other stimulators and inhibitors of P-gp, and mutant I306C can be protected from labeling by verapamil and the other substrates and inhibitors.
A model to explain the activated state of P-gp is shown in Fig. 5 . In the resting state (state I), P-gp can bind ATP with normal affinity but ATPase activity is low because the opposing signature "LSGGQ" motifs are farther away from the Walker A sites in the nucleotide-binding domains (NBDs) (33, 37) . Binding of verapamil in the TM segments induces conformation changes in the NBDs to bring the LSGGQ and Walker A sequences closer (state II) and promote ATP hydrolysis (38, 39) . ATP hydrolysis then changes the conformation of the TM segments (26, 40) ATPases such as the sarcoplasmic reticulum (SERCA) Ca-ATPase. In the P-type ATPases, ATP hydrolysis is linked to conformational changes in the calcium-binding site, but Pi is not released until after vectorial transport of calcium (43, 44 ).
This study also shows that TM5 must contribute residues to the drug-binding site, since other substrates and inhibitors could protect I306C from labeling by MTS-verapamil.
We had predicted that I306C likely lined the drug-binding site because it could be crosslinked to other cysteines in TMs 10, 11 and 12 with thiol-reactive cross-linker substrates (20) . 
